Evidence map›Paper›PMID 42711894›Full record

ArticleRadiology and oncology2026

Electrochemotherapy for cutaneous tumors combined with tumor irradiation before or after treatment: feasibility, safety, and effectiveness.

Giulia Bertino, Marta Minuti, Julie Gehl, Erika Kis, Hadrian Nassabi, Michele Pio Grieco, Giuseppe Riva, Matteo Mascherini, Francesca De Terlizzi, Maja Cemazar and 1 more

Abstract read
In one paragraph

Article in Radiology and oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giulia Bertino1Department of Otolaryngology Head and Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Marta Minuti1Department of Otolaryngology Head and Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Julie Gehl2Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark.
Erika Kis4Department of Dermatology and Allergology, Albert Szent-Györgyi Medical School, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged, Hungary.
Hadrian Nassabi5Department of Dermatology and Plastic Surgery, SRH- Waldklinikum, Gera, Germany.
Michele Pio Grieco6UOC Chirurgia Plastica e Skin Cancer Unit, IRCCS CROB Centro Riferimento Oncologico Basilicata, Rionero in Vulture (PZ), Italy.
Giuseppe Riva7Division of Otorhinolaryngology, Department of Surgical Sciences, AOU Città della Salute e della Scienza of Turin, Torino, Italy.
Matteo Mascherini8Department of Surgery, IRCCS AOM Liguria, Genoa, Italy.
Francesca De Terlizzi9IGEA Biophysics Lab. Carpi, Modena, Italy.
Maja Cemazar10Department of Experimental Oncology, Institute of Oncology Ljubljana, Slovenia.
Gregor Sersa10Department of Experimental Oncology, Institute of Oncology Ljubljana, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElectrochemotherapy (ECT) can be performed on tumors in patients that precedes tumor irradiation or on recurrent tumors after tumor irradiation. In this study we evaluated the feasibility, safety and effectiveness of the combined ECT and tumor irradiation (radiotherapy, RT) on different tumors in the head and neck region. PATIENTS AND

methodsFor the present cohort analysis, patients were selected from the Insp-ECT database, based on the following criteria: presence of head and neck lesions of any histological origin, treatment with both ECT and RT in any sequence, and a maximum interval of 12 months between the two treatments. The patients were treated with ECT followed by RT (ECT → RT) or RT followed by ECT (RT → ECT), in both cases because the first treatment resulted in incomplete response or subsequent relapse. In the case of ECT → RT the meantime interval was 5.7 months and in the case of RT → ECT 7.6 months. The minimal time interval between the treatments was 1 month.

resultsTreatment with ECT with bleomycin was feasible in all patients, treated either before or after RT. Included were 37 patients with the head and neck lesions. The combined treatment was performed predominantly on older population of patients with the age range from 50 to 96 years, median over 80 years. Importantly, in the group ECT → RT the major reason for RT was partial response (67%) after ECT. While, in the RT → ECT group the major reason for subsequent ECT was 58% of stable or progressive disease (failure to treatment). In both groups local symptoms decreased, like ulceration, odour and suppuration of tumors. In the ECT → RT group, the short-term response after 2 months was high, with 89% objective responses. In contrast, the RT → ECT group had a significantly lower rate, with 58% objective responses. At 24-month progression free survival (PFS) was 68% in the ECT → RT group and 20% in the RT → ECT group (p = 0.0101). The overall progression free survival Kaplan-Meier curves also differed significantly (log-rank p = 0.0232).

conclusionsThe combined treatment of ECT and RT is feasible, safe, and effective in elderly patients. The findings suggest that ECT may have particular value as a neoadjuvant treatment before RT, especially for bulky, ulcerated, or symptomatic lesions in this population.

Indexed as

Antibiotics, AntineoplasticBleomycinElectrochemotherapyHead and Neck NeoplasmsSkin NeoplasmsAgedAged, 80 and overCombined Modality TherapyFeasibility StudiesFemaleHumansMaleMiddle AgedTreatment OutcomeAntibiotics, AntineoplasticBleomycincutaneous tumorselectrochemotherapyneoadjuvant treatmentsalvage therapytumor controltumor irradiation

Identifiers

PMID42711894
PMCPMC13554300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.